Guizhi Fuling

Presentation Slides

Chinese Medicine Research Hub

Meta-Analysis

Combining Chinese herbal medicines with high-intensity focused ultrasound improves the clinical effectiveness in treating uterine fibroids.

2025 Phytomedicine Efficacy of Chinese herbal medicines combined with high-intensity focused ultrasound for patients with uterine fibroids: A meta-analysis with core herbs exploration
Huang YT, Wang MC, Liao JA, Chen WC, Chou YT, Cheng WJ

Chinese Medicine Research Hub

Systematic Review

Guizhi Fuling Wan, a traditional Chinese herbal formula, can inhibit endometriosis growth and enhance the effects of western medicines used to treat the condition.

2024 Journal of Ethnopharmacology Potential Mechanisms of Guizhi Fuling Wan in Treating Endometriosis: An Analysis Based on TCMSP and DisGeNET Databases
Yee JL, Huang CY, Yu YC, Huang SJ

Chinese Medicine Research Hub

Randomised Controlled Trial

Gui Zhi Fu Ling Wan significantly reduced menstrual pain in primary dysmenorrhea patients with heat-burning blood-stasis syndrome, without notable adverse effects.

2023 Journal of Ethnopharmacology Effect of Guizhi Fuling Wan in primary dysmenorrhea: A randomized controlled trial
Luo Y, Mao P, Chen P, Li C, Fu X, Zhuang M

Chinese Medicine Research Hub

Systematic Review

The combination of Guizhi Fuling Capsule with low-dose mifepristone is more effective and safe in the treatment of uterine fibroids.

2023 BMC Complementary Medicine and Therapies The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials
Lei Y, Yang L, Yang H, Li M, Ou L, Bai Y, Dong T, Gao F, Wei P

Chinese Medicine Research Hub

Randomised Controlled Trial

The herbal formula Guizhi Fuling Wan safely reduces uterine fibroid-related symptoms and fibroid volume at both low and conventional doses.

2022 Journal of Ethnopharmacology Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids
Meng W, Lin WL, Yeung WF, Zhang Y, Ng EHY, Lee YPE, Zhang ZJ, Rong J, Lao L

Chinese Medicine Research Hub

Animal Study

Combining traditional Chinese medicine Guizhi Fuling Wan with western hormonal therapies can potentially reduce their individual effectiveness in treating endometriosis.

2022 Taiwanese Journal of Obstetrics and Gynecology Combinatory effects of current regimens and Guizhi Fuling Wan on the development of endometriosis
Chen CC, Huang CY, Shiu LY, Yu YC, Lai JC, Chang CC, Fu CF, Huang SJ

Chinese Medicine Research Hub

Network Pharmacology

Gui Zhi Fu Ling Wan treats adenomyosis by intervening in local estrogen signalling pathways and affecting estrogen resistance via myometrium signalling pathways.

2021 Evidence-Based Complementary and Alternative Medicine Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
Wang H, Zhang J, Zhu Q, Fu X, Li C

Chinese Medicine Research Hub

Network Pharmacology

Guizhi Fuling Wan, a traditional herbal formula, can improve peripheral blood flow in menopausal hot flush sufferers, despite not changing the frequency or severity of the flushes.

2019 Biomedicines A Classic Herbal Formula Guizhi Fuling Wan for Menopausal Hot Flushes: From Experimental Findings to Clinical Applications
Li , Hung , Li , Yang

Chinese Medicine Research Hub

Systematic Review

Guizhi Fuling formula shows potential in treating uterine fibroids.

2014 BMC Complementary Medicine and Therapies Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: a systematic review of randomised clinical trials
Chen NN, Han M, Yang H, Yang GY, Wang YY, Wu XK, Liu JP

Executive Summary

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Guizhi Fuling" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Guizhi Fuling" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Guizhi Fuling" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A Meta-Analysis published in 2025 in the journal Phytomedicine found that Combining Chinese herbal medicines with high-intensity focused ultrasound improves the clinical effectiveness in treating uterine fibroids. Researchers conducted a meta-analysis of 19 randomized controlled trials, in English and Chinese databases until May 2024, to assess the combined effects of high-intensity focused ultrasound (HIFU) and Chinese herbal medicines (CHMs) on uterine fibroids. The quality of these studies was evaluated using the Cochrane Risk of Bias 2 tool, and the results were analyzed using RevMan 5.4 software. The primary outcomes considered were changes in fibroid volume and clinical effectiveness, while secondary outcomes included changes in uterus volume, Traditional Chinese Medicine syndrome scores, recurrence rates, and adverse reactions. The study found that the combination of CHMs and HIFU had a greater impact on reducing uterine fibroid volumes and had a higher clinical efficacy rate than HIFU therapy alone. A total of 26 single herbs and 93 commonly used herbal combinations were identified. The most frequently used herbs were: Curcumae Rhizoma, Sparganii Rhizoma, Astragalus membranaceus, Poria cocos, Paeonia suffruticosa, and Trionyx sinensis. Furthermore, the study proposed a dual-phase mechanism through which core CHMs might enhance the effectiveness of HIFU. This mechanic involves promoting apoptosis during thermal ablation and modulating fibrotic and proliferation signaling pathways in the post-ablation phase.

A Systematic Review published in 2024 in the journal Journal of Ethnopharmacology found that Guizhi Fuling Wan, a traditional Chinese herbal formula, can inhibit endometriosis growth and enhance the effects of western medicines used to treat the condition. In the methodology, a bibliographic assessment of publications on "Guizhi Fuling Wan" and "endometriosis" indexed in international and chinese databases was conducted. Out of these, five pre-clinical studies and thirteen clinical were selected. Thereafter, targeted molecules of each herb in the formula were extracted from a Traditional Chinese Medicine Systems Pharmacology Database and compared with endometriosis-related genes from DisGeNET. To expose potential therapeutic mechanisms of Guizhi Fuling Wan, pathway and gene ontology analyses were performed using David Bioinformatics Resources. In the results discussion, it was found that both pre-clinical and clinical studies suggested that Guizhi Fuling Wan can inhibit the growth of endometriotic lesions by modulating immunity, apoptosis-regulating molecules, and angiogenesis-associated factors, while also enhancing the effects of western medicines for endometriosis. The formula likely achieves this through its impact on key pathways involved in diabetes complications, Kaposi sarcoma-associated herpesvirus infection, human cytomegalovirus infection, and atherosclerosis, which all regulate inflammation, angiogenesis, and apoptosis. The review also notes a strong connection between endometriosis and abnormal inflammatory, angiogenic, and apoptotic activities.

A Randomised Controlled Trial published in 2023 in the journal Journal of Ethnopharmacology found that Gui Zhi Fu Ling Wan significantly reduced menstrual pain in primary dysmenorrhea patients with heat-burning blood-stasis syndrome, without notable adverse effects. In the methodology, a randomized, double-blinded, placebo-controlled trial was conducted. Eligible patients suffering from primary dysmenorrhea with heat-burning blood-stasis syndrome were randomly placed into two groups – one received Guizhi Fuling Wan, the other a placebo, administered twice daily across three menstrual cycles, with a 3-month follow-up. The primary measurement was the change in pain intensity from the beginning to the 6th month, gauged by using a Visual Analog Scale. In the discussion of results, data showed that the pain intensity (measured using Visual Analog Scale) significantly decreased in the Guizhi Fuling Wan group compared to the placebo over the 6 month period. Secondary measurements also indicated a greater reduction in Cox Menstrual Symptom Scale, Self-rating Anxiety Scale, and traditional Chinese medicine syndrome scores in the Guizhi Fuling Wan group compared to the placebo. However, there was no significant difference between the two groups when measuring the Self-rating Depression Scale. Furthermore, no serious adverse events were observed during the trial.

A Systematic Review published in 2023 in the journal BMC Complementary Medicine and Therapies found that The combination of Guizhi Fuling Capsule with low-dose mifepristone is more effective and safe in the treatment of uterine fibroids. This study summarises the findings from twenty-eight randomized controlled trials, involving a total of 2813 patients, focusing on the efficacy and safety of Guizhi Fuling Capsule combined with low-dose mifepristone in treating uterine fibroids. The trials were identified through a comprehensive search of eight literature databases and two clinical trial registries, followed by a data analysis using several software tools. The results indicate that this combination yielded a significant reduction in follicle stimulating hormone, estradiol, progesterone, luteinizing hormone, uterine fibroids' volume, uterine volume, and menstrual flow. Furthermore, it increased the clinical efficiency rate. Compared to low-dose mifepristone alone, the combination did not significantly increase the incidence of adverse drug reactions, indicating its relative safety.

A Randomised Controlled Trial published in 2022 in the journal Journal of Ethnopharmacology found that The herbal formula Guizhi Fuling Wan safely reduces uterine fibroid-related symptoms and fibroid volume at both low and conventional doses. This double-blind, dosage-controlled trial performed in an outpatient clinic of traditional Chinese medicine in Hong Kong centered on women who had been diagnosed with symptomatic uterine fibroids according to the World Health Organization's International Classification of Diseases. Participants were randomly divided into two groups, with each group prescribed either a low or conventional daily dose of a modified version of the herbal formula Guizhi Fuling Wan for a span of 16 weeks. A comparison of the two groups revealed no significant differences in perceived symptom severity, quality of life, menstrual bleeding, pain severity, changes in fibroid volume, hemoglobin levels, or hormone levels by the end of the trial period. However, significant improvements were noted within both groups in relation to their baseline measurements in these areas. It was of particular note that the group receiving the lower dose of the herbal supplement reported a greater improvement in their traditional Chinese medicine syndrome score. There were no severe side effects reported in association with the blend.

A Animal Study published in 2022 in the journal Taiwanese Journal of Obstetrics and Gynecology found that Combining traditional Chinese medicine Guizhi Fuling Wan with western hormonal therapies can potentially reduce their individual effectiveness in treating endometriosis. In this study, endometriosis was induced in mice. This was achieved by suturing endometrial tissue onto the peritoneal wall of the subjects. The mice were then treated with varying combinations of Guizhi Fuling Wan (GFW), a traditional Chinese medicine, and current western hormonal therapies for a period of 28 days. The results show that the traditional Chinese medicine Guizhi Fuling Wan (GFW), hormonal therapies, and combinations of these two were able to inhibit the development of endometriosis. They also observed that these treatments, either alone or in combination, could inhibit the expression of Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Endothelial Growth Factor (VEGF). These agents could also reduce the population of macrophages in the peritoneal fluid while enhancing the B-cell population. However, when GFW was combined with hormonal therapies, it was observed that the efficiency of each agent individually was potentially reduced.

A Network Pharmacology published in 2021 in the journal Evidence-Based Complementary and Alternative Medicine found that Gui Zhi Fu Ling Wan treats adenomyosis by intervening in local estrogen signalling pathways and affecting estrogen resistance via myometrium signalling pathways. This study utilized network pharmacology, molecular docking and animal experiments to understand the treatment mechanisms of Guizhi Fuling Wan on adenomyosis. Initially, key indices and target components of the traditional Chinese medicine were identified through various databases, which resulted in isolation of 55 active ingredients and 44 targets specifically related to adenomyosis treatment. These components were then subjected to protein interaction analysis and compound-hub target network constructions. Main active elements and hub targets were subsequently studied with molecular docking tech. The pathway enrichment analysis showed that the medicinal effects were primarily linked to estrogen signaling, endocrine resistance, and a specific tyrosine kinase signaling pathway. The molecular docking revealed that significant compounds of Guizhi Fuling Wan had a strong binding ability with a couple of cellular receptors. Animal trials indicated that this medicine could reduce abnormal infiltration of specific cells without interrupting normal sexual cycles. These results point towards the importance of the estrogen signaling pathway and cell receptors in the treatment capabilities of Guizhi Fuling Wan.

A Network Pharmacology published in 2019 in the journal Biomedicines found that Guizhi Fuling Wan, a traditional herbal formula, can improve peripheral blood flow in menopausal hot flush sufferers, despite not changing the frequency or severity of the flushes. The methodology used in this study involved a comprehensive literature search across 20 English and Chinese databases for relative clinical and experimental studies. From the nearly 13,000 studies identified, only 46 were evaluated as relevant and thus included in the review. These articles were comprised of seven clinical studies detailing Guizhi Fuling Wan's effects on menopausal hot flushes and 35 phytochemical analysis studies that identified the 169 chemical compounds in the herbal formula. Four experimental studies were also utilized to discover the potential therapeutic effects and target proteins/cytokines related to these hot flushes. The findings indicate that Guizhi Fuling Wan, despite exhibiting no significant impact on the frequency or severity of menopausal hot flushes, may have positive effects on peripheral blood flow. The blood flow improvements were specifically noted in the fingertips, jaw, and toes. Additionally, the analysis of the herbal formula revealed 169 distinct chemical compounds. Through experimental studies, potential therapeutic effects on target proteins/cytokines - including estrogen receptor beta with genetic variation, the calcitonin gene-related peptide receptor, and interleukin-8, were further highlighted. However, these therapeutic effects were inconsistent across different studies, which may be due to dosage differences and genotype variation.

A Systematic Review published in 2014 in the journal BMC Complementary Medicine and Therapies found that Guizhi Fuling formula shows potential in treating uterine fibroids. This comprehensive review analyzed 21 trials (including three meta-analyses and eight individual trials) regarding the effectiveness of Guizhi Fuling Formula combined with mifepristone in treating uterine fibroids. The results indicated potential benefits in reducing fibroid volume and uterine size compared to mifepristone alone. However, the overall methodological quality of the included trials was deemed poor, with issues such as unclear randomization procedures and lack of blinding. Further high-quality clinical trials with larger sample sizes are recommended to provide more conclusive evidence on the efficacy of this treatment approach for uterine fibroids.

Moderation Tools

Topic